| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Atrial Fibrillation | 62 | 2025 | 5186 | 5.110 |
Why?
|
| Defibrillators, Implantable | 27 | 2024 | 1497 | 4.240 |
Why?
|
| Pacemaker, Artificial | 17 | 2023 | 829 | 4.160 |
Why?
|
| Anti-Arrhythmia Agents | 27 | 2021 | 772 | 3.720 |
Why?
|
| Amiodarone | 11 | 2021 | 216 | 2.580 |
Why?
|
| Arrhythmias, Cardiac | 30 | 2022 | 2255 | 2.430 |
Why?
|
| Electrocardiography, Ambulatory | 15 | 2015 | 582 | 2.150 |
Why?
|
| Electrocardiography | 42 | 2024 | 6409 | 2.100 |
Why?
|
| Sarcoidosis | 6 | 2023 | 533 | 1.560 |
Why?
|
| Catheter Ablation | 20 | 2025 | 2787 | 1.550 |
Why?
|
| Thromboembolism | 6 | 2019 | 1001 | 1.420 |
Why?
|
| Anticoagulants | 15 | 2021 | 4856 | 1.340 |
Why?
|
| Cardiac Pacing, Artificial | 11 | 2022 | 882 | 1.230 |
Why?
|
| Heart Rate | 18 | 2021 | 4203 | 1.060 |
Why?
|
| Heart Conduction System | 10 | 2021 | 1007 | 1.060 |
Why?
|
| Electric Countershock | 7 | 2019 | 536 | 1.030 |
Why?
|
| Cardiomyopathies | 10 | 2023 | 2068 | 0.960 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2018 | 363 | 0.950 |
Why?
|
| Tachycardia, Ventricular | 9 | 2024 | 1313 | 0.860 |
Why?
|
| Atrial Flutter | 7 | 2014 | 253 | 0.840 |
Why?
|
| Death, Sudden, Cardiac | 10 | 2022 | 1568 | 0.830 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 11 | 2024 | 511 | 0.790 |
Why?
|
| Warfarin | 5 | 2021 | 1494 | 0.700 |
Why?
|
| Prosthesis-Related Infections | 2 | 2023 | 497 | 0.680 |
Why?
|
| Cardiac Resynchronization Therapy | 3 | 2020 | 562 | 0.670 |
Why?
|
| Bradycardia | 3 | 2011 | 304 | 0.660 |
Why?
|
| Electrophysiology | 4 | 2017 | 1264 | 0.630 |
Why?
|
| Angioplasty, Balloon, Coronary | 12 | 2010 | 1721 | 0.610 |
Why?
|
| Syncope | 8 | 2011 | 431 | 0.600 |
Why?
|
| Tricuspid Valve | 2 | 2018 | 421 | 0.590 |
Why?
|
| Heart Ventricles | 7 | 2024 | 3833 | 0.580 |
Why?
|
| Long QT Syndrome | 4 | 2020 | 474 | 0.580 |
Why?
|
| Telemetry | 1 | 2018 | 201 | 0.550 |
Why?
|
| Tachycardia, Atrioventricular Nodal Reentry | 4 | 2021 | 148 | 0.540 |
Why?
|
| Phenethylamines | 1 | 2016 | 95 | 0.510 |
Why?
|
| Stroke | 8 | 2020 | 9739 | 0.500 |
Why?
|
| Atrial Function | 2 | 2013 | 98 | 0.500 |
Why?
|
| Humans | 182 | 2025 | 765926 | 0.500 |
Why?
|
| Torsades de Pointes | 3 | 2020 | 78 | 0.480 |
Why?
|
| Neuromuscular Diseases | 1 | 2017 | 260 | 0.470 |
Why?
|
| Heart Diseases | 5 | 2021 | 2818 | 0.460 |
Why?
|
| Specialization | 1 | 2019 | 779 | 0.450 |
Why?
|
| Heart Failure | 11 | 2022 | 11837 | 0.450 |
Why?
|
| Bundle-Branch Block | 6 | 2021 | 280 | 0.450 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 1 | 2015 | 122 | 0.440 |
Why?
|
| Early Diagnosis | 1 | 2019 | 1186 | 0.440 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2022 | 1338 | 0.440 |
Why?
|
| Heart Atria | 5 | 2018 | 1363 | 0.440 |
Why?
|
| Sotalol | 2 | 2021 | 47 | 0.430 |
Why?
|
| Pulmonary Veins | 6 | 2025 | 757 | 0.430 |
Why?
|
| Vascular Diseases | 1 | 2022 | 1161 | 0.430 |
Why?
|
| Monitoring, Physiologic | 3 | 2018 | 1793 | 0.420 |
Why?
|
| Myocardial Contraction | 3 | 2013 | 1516 | 0.420 |
Why?
|
| Continuous Positive Airway Pressure | 2 | 2015 | 581 | 0.410 |
Why?
|
| Coronary Artery Bypass | 2 | 2020 | 2188 | 0.400 |
Why?
|
| Cardiac Surgical Procedures | 3 | 2021 | 3682 | 0.390 |
Why?
|
| Aged | 82 | 2025 | 171163 | 0.390 |
Why?
|
| Equipment Failure | 5 | 2019 | 580 | 0.390 |
Why?
|
| Risk Factors | 40 | 2023 | 74850 | 0.390 |
Why?
|
| Treatment Outcome | 42 | 2024 | 65194 | 0.380 |
Why?
|
| Myocardial Infarction | 17 | 2011 | 11508 | 0.380 |
Why?
|
| Vagus Nerve Diseases | 1 | 2011 | 5 | 0.370 |
Why?
|
| Electrodes, Implanted | 1 | 2015 | 834 | 0.360 |
Why?
|
| Antithrombins | 1 | 2013 | 295 | 0.360 |
Why?
|
| Physician's Role | 1 | 2017 | 925 | 0.350 |
Why?
|
| Male | 102 | 2025 | 363815 | 0.350 |
Why?
|
| Ventricular Function, Left | 7 | 2024 | 3930 | 0.330 |
Why?
|
| Wine | 1 | 2010 | 172 | 0.320 |
Why?
|
| Tachycardia | 4 | 2008 | 598 | 0.320 |
Why?
|
| Electrodes | 1 | 2011 | 609 | 0.320 |
Why?
|
| Middle Aged | 76 | 2024 | 223016 | 0.310 |
Why?
|
| Time Factors | 25 | 2020 | 40097 | 0.310 |
Why?
|
| Prosthesis Failure | 3 | 2013 | 1194 | 0.300 |
Why?
|
| Benzimidazoles | 1 | 2013 | 862 | 0.300 |
Why?
|
| Postoperative Complications | 5 | 2024 | 15802 | 0.300 |
Why?
|
| Female | 95 | 2025 | 396141 | 0.290 |
Why?
|
| Ventricular Dysfunction, Left | 7 | 2010 | 2136 | 0.290 |
Why?
|
| Sleep Apnea, Obstructive | 3 | 2017 | 1898 | 0.290 |
Why?
|
| Stroke Volume | 12 | 2024 | 5595 | 0.280 |
Why?
|
| Cardiology | 2 | 2016 | 1696 | 0.280 |
Why?
|
| Wolfram Syndrome | 1 | 2006 | 14 | 0.270 |
Why?
|
| Quality of Life | 7 | 2019 | 13463 | 0.270 |
Why?
|
| Direct Service Costs | 1 | 2006 | 61 | 0.270 |
Why?
|
| Sulfonamides | 1 | 2016 | 1979 | 0.260 |
Why?
|
| Myocarditis | 2 | 2023 | 803 | 0.250 |
Why?
|
| United States | 31 | 2025 | 72909 | 0.250 |
Why?
|
| Hospitalization | 9 | 2024 | 10810 | 0.240 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 3 | 2021 | 941 | 0.240 |
Why?
|
| Cardiovascular Diseases | 8 | 2019 | 15645 | 0.240 |
Why?
|
| Drug Delivery Systems | 1 | 2015 | 2206 | 0.230 |
Why?
|
| Healthcare Disparities | 1 | 2020 | 3407 | 0.230 |
Why?
|
| Current Procedural Terminology | 1 | 2025 | 100 | 0.230 |
Why?
|
| Canada | 4 | 2020 | 2120 | 0.220 |
Why?
|
| Aged, 80 and over | 31 | 2024 | 59496 | 0.220 |
Why?
|
| Heart Septal Defects, Atrial | 1 | 2006 | 452 | 0.210 |
Why?
|
| Outpatients | 2 | 2003 | 1595 | 0.210 |
Why?
|
| Electronics | 2 | 2022 | 314 | 0.210 |
Why?
|
| Electric Power Supplies | 2 | 2015 | 94 | 0.210 |
Why?
|
| Equipment Design | 5 | 2019 | 3490 | 0.200 |
Why?
|
| Health Status Indicators | 1 | 2008 | 967 | 0.200 |
Why?
|
| Myocardial Stunning | 1 | 2002 | 67 | 0.200 |
Why?
|
| Medical Records | 1 | 2008 | 1408 | 0.200 |
Why?
|
| Prospective Studies | 27 | 2020 | 54807 | 0.200 |
Why?
|
| Siblings | 1 | 2006 | 828 | 0.200 |
Why?
|
| Veins | 2 | 2022 | 768 | 0.200 |
Why?
|
| Health Services Accessibility | 2 | 2019 | 5509 | 0.200 |
Why?
|
| Aortic Valve Stenosis | 3 | 2022 | 2022 | 0.190 |
Why?
|
| Suction | 1 | 2023 | 268 | 0.190 |
Why?
|
| Ventricular Fibrillation | 3 | 2011 | 538 | 0.190 |
Why?
|
| Drug Approval | 1 | 2009 | 819 | 0.190 |
Why?
|
| Action Potentials | 4 | 2020 | 1837 | 0.190 |
Why?
|
| Decision Making | 3 | 2012 | 3955 | 0.190 |
Why?
|
| Flecainide | 2 | 2021 | 41 | 0.190 |
Why?
|
| Pyridines | 1 | 2013 | 2885 | 0.190 |
Why?
|
| Drug Utilization Review | 1 | 2003 | 248 | 0.190 |
Why?
|
| Recurrence | 10 | 2017 | 8492 | 0.190 |
Why?
|
| Retrospective Studies | 25 | 2025 | 81537 | 0.190 |
Why?
|
| Comorbidity | 9 | 2024 | 10575 | 0.190 |
Why?
|
| Health Resources | 2 | 2007 | 950 | 0.180 |
Why?
|
| Mitral Valve Prolapse | 2 | 2016 | 213 | 0.180 |
Why?
|
| Magnetic Resonance Imaging, Cine | 3 | 2016 | 1093 | 0.170 |
Why?
|
| Administration, Oral | 3 | 2015 | 4016 | 0.170 |
Why?
|
| Device Removal | 2 | 2017 | 643 | 0.170 |
Why?
|
| Vasoconstrictor Agents | 2 | 2016 | 653 | 0.170 |
Why?
|
| Incidence | 11 | 2023 | 21513 | 0.170 |
Why?
|
| Atrioventricular Block | 1 | 2022 | 141 | 0.170 |
Why?
|
| Age Factors | 5 | 2020 | 18382 | 0.170 |
Why?
|
| Pilot Projects | 5 | 2018 | 8724 | 0.160 |
Why?
|
| Follow-Up Studies | 14 | 2024 | 39228 | 0.160 |
Why?
|
| Health Behavior | 1 | 2011 | 2649 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 10727 | 0.160 |
Why?
|
| Sex Factors | 4 | 2012 | 10611 | 0.160 |
Why?
|
| Risk Assessment | 9 | 2020 | 24275 | 0.160 |
Why?
|
| Vectorcardiography | 3 | 2024 | 48 | 0.160 |
Why?
|
| Azithromycin | 1 | 2020 | 202 | 0.160 |
Why?
|
| Models, Statistical | 1 | 2013 | 5088 | 0.160 |
Why?
|
| Exercise | 3 | 2011 | 5936 | 0.160 |
Why?
|
| Patient Identification Systems | 1 | 2019 | 75 | 0.160 |
Why?
|
| Predictive Value of Tests | 12 | 2018 | 15401 | 0.160 |
Why?
|
| Echocardiography | 6 | 2016 | 5040 | 0.150 |
Why?
|
| Pericarditis | 1 | 2020 | 135 | 0.150 |
Why?
|
| Safety | 3 | 2011 | 1157 | 0.150 |
Why?
|
| Dyspnea | 1 | 2006 | 1351 | 0.150 |
Why?
|
| Medication Therapy Management | 1 | 2019 | 131 | 0.150 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 4041 | 0.150 |
Why?
|
| Coronary Disease | 5 | 2007 | 5919 | 0.140 |
Why?
|
| Thrombolytic Therapy | 2 | 2022 | 2050 | 0.140 |
Why?
|
| Patient Selection | 5 | 2019 | 4248 | 0.140 |
Why?
|
| Health Status | 1 | 2010 | 4085 | 0.140 |
Why?
|
| Patient Satisfaction | 2 | 2012 | 3477 | 0.140 |
Why?
|
| Heart Block | 3 | 2008 | 391 | 0.140 |
Why?
|
| Heart Arrest | 3 | 2016 | 1516 | 0.140 |
Why?
|
| Algorithms | 9 | 2022 | 14064 | 0.140 |
Why?
|
| Cost of Illness | 1 | 2006 | 1949 | 0.130 |
Why?
|
| United States Food and Drug Administration | 2 | 2019 | 1673 | 0.130 |
Why?
|
| Myocardial Reperfusion | 3 | 2007 | 338 | 0.130 |
Why?
|
| Hydroxychloroquine | 1 | 2020 | 429 | 0.130 |
Why?
|
| Hospital Units | 1 | 2017 | 141 | 0.130 |
Why?
|
| Multivariate Analysis | 9 | 2009 | 12059 | 0.130 |
Why?
|
| Tachycardia, Supraventricular | 1 | 2018 | 272 | 0.130 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 2 | 2006 | 153 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2013 | 36547 | 0.120 |
Why?
|
| Prognosis | 10 | 2013 | 29890 | 0.120 |
Why?
|
| Muscular Dystrophies | 1 | 2017 | 392 | 0.120 |
Why?
|
| Observation | 1 | 2017 | 309 | 0.120 |
Why?
|
| Registries | 7 | 2013 | 8346 | 0.120 |
Why?
|
| Chi-Square Distribution | 2 | 2019 | 3430 | 0.120 |
Why?
|
| Hemorrhage | 2 | 2020 | 3466 | 0.120 |
Why?
|
| Drug Monitoring | 2 | 2014 | 960 | 0.110 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2019 | 641 | 0.110 |
Why?
|
| Chest Pain | 2 | 2017 | 1102 | 0.110 |
Why?
|
| Myocardium | 3 | 2017 | 4764 | 0.110 |
Why?
|
| Sampling Studies | 1 | 2015 | 610 | 0.110 |
Why?
|
| Shock | 1 | 2016 | 316 | 0.110 |
Why?
|
| Coronary Angiography | 6 | 2020 | 4498 | 0.110 |
Why?
|
| Pharmaceutical Preparations | 1 | 2021 | 1084 | 0.110 |
Why?
|
| Needs Assessment | 1 | 2019 | 1140 | 0.110 |
Why?
|
| Signal Processing, Computer-Assisted | 2 | 2018 | 1457 | 0.110 |
Why?
|
| Atrial Appendage | 2 | 2014 | 284 | 0.100 |
Why?
|
| Logistic Models | 6 | 2013 | 13273 | 0.100 |
Why?
|
| Adult | 25 | 2022 | 223088 | 0.100 |
Why?
|
| Patient Care Team | 2 | 2017 | 2515 | 0.100 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 3109 | 0.100 |
Why?
|
| Severity of Illness Index | 6 | 2017 | 15878 | 0.100 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 1464 | 0.100 |
Why?
|
| Half-Life | 1 | 2013 | 645 | 0.100 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 3231 | 0.100 |
Why?
|
| Medicare | 3 | 2025 | 6815 | 0.100 |
Why?
|
| Interdisciplinary Studies | 1 | 2012 | 85 | 0.100 |
Why?
|
| Emergency Medical Services | 1 | 2003 | 1937 | 0.100 |
Why?
|
| Echocardiography, Transesophageal | 4 | 2016 | 1093 | 0.100 |
Why?
|
| Infectious Disease Medicine | 1 | 2012 | 50 | 0.100 |
Why?
|
| Consensus | 1 | 2021 | 3202 | 0.090 |
Why?
|
| Respiratory Insufficiency | 1 | 2020 | 1241 | 0.090 |
Why?
|
| Emergency Service, Hospital | 5 | 2017 | 7871 | 0.090 |
Why?
|
| Feasibility Studies | 2 | 2018 | 5300 | 0.090 |
Why?
|
| Hong Kong | 1 | 2011 | 169 | 0.090 |
Why?
|
| Endomyocardial Fibrosis | 1 | 2011 | 41 | 0.090 |
Why?
|
| Ambulatory Care | 2 | 2007 | 2778 | 0.090 |
Why?
|
| Gemfibrozil | 1 | 1991 | 30 | 0.090 |
Why?
|
| Exercise Test | 2 | 2011 | 2185 | 0.090 |
Why?
|
| Lipoproteins | 3 | 1992 | 870 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 3 | 2007 | 7423 | 0.090 |
Why?
|
| Amitriptyline | 1 | 2011 | 110 | 0.090 |
Why?
|
| Stents | 5 | 2009 | 3191 | 0.090 |
Why?
|
| Fibrosis | 3 | 2016 | 2073 | 0.090 |
Why?
|
| Probucol | 1 | 1990 | 25 | 0.090 |
Why?
|
| Altitude | 1 | 2011 | 162 | 0.090 |
Why?
|
| Young Adult | 3 | 2022 | 59857 | 0.090 |
Why?
|
| Residence Characteristics | 1 | 2020 | 2116 | 0.080 |
Why?
|
| Europe | 2 | 2020 | 3430 | 0.080 |
Why?
|
| Lipoproteins, VLDL | 1 | 1991 | 198 | 0.080 |
Why?
|
| Survival Analysis | 6 | 2011 | 10086 | 0.080 |
Why?
|
| Propafenone | 2 | 2007 | 27 | 0.080 |
Why?
|
| Adrenergic Uptake Inhibitors | 1 | 2011 | 187 | 0.080 |
Why?
|
| Inpatients | 1 | 2001 | 2563 | 0.080 |
Why?
|
| Cyclopropanes | 1 | 2011 | 436 | 0.080 |
Why?
|
| Drug Synergism | 1 | 2013 | 1751 | 0.080 |
Why?
|
| Out-of-Hospital Cardiac Arrest | 2 | 2011 | 341 | 0.080 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2013 | 878 | 0.080 |
Why?
|
| Heart Transplantation | 1 | 2023 | 3310 | 0.080 |
Why?
|
| Prosthesis Implantation | 2 | 2011 | 594 | 0.080 |
Why?
|
| Decision Support Techniques | 2 | 2011 | 2004 | 0.080 |
Why?
|
| Referral and Consultation | 1 | 2022 | 3615 | 0.080 |
Why?
|
| Patient-Centered Care | 1 | 2019 | 1447 | 0.080 |
Why?
|
| Tachycardia, Ectopic Atrial | 1 | 2009 | 65 | 0.080 |
Why?
|
| Primary Prevention | 2 | 2013 | 1187 | 0.080 |
Why?
|
| Posture | 2 | 2006 | 955 | 0.080 |
Why?
|
| Health Care Costs | 3 | 2007 | 3241 | 0.080 |
Why?
|
| Evidence-Based Medicine | 2 | 2013 | 3690 | 0.080 |
Why?
|
| Heart Function Tests | 1 | 2009 | 317 | 0.080 |
Why?
|
| Cohort Studies | 9 | 2020 | 41680 | 0.080 |
Why?
|
| Ethanolamines | 1 | 2008 | 152 | 0.070 |
Why?
|
| Intracranial Embolism | 1 | 2009 | 188 | 0.070 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 8037 | 0.070 |
Why?
|
| Heart | 2 | 2011 | 4419 | 0.070 |
Why?
|
| Coated Materials, Biocompatible | 2 | 2007 | 314 | 0.070 |
Why?
|
| Odds Ratio | 2 | 2011 | 9656 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2021 | 10380 | 0.070 |
Why?
|
| Hydrocortisone | 1 | 2016 | 1832 | 0.070 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2022 | 3230 | 0.070 |
Why?
|
| Hypertriglyceridemia | 1 | 1991 | 292 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2022 | 3530 | 0.070 |
Why?
|
| Albuterol | 1 | 2008 | 211 | 0.070 |
Why?
|
| Boston | 4 | 2017 | 9334 | 0.070 |
Why?
|
| Chromium Alloys | 1 | 2007 | 71 | 0.070 |
Why?
|
| Filtration | 1 | 2008 | 227 | 0.070 |
Why?
|
| Papillary Muscles | 1 | 2008 | 192 | 0.070 |
Why?
|
| Data Collection | 2 | 2006 | 3318 | 0.070 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 637 | 0.070 |
Why?
|
| Causality | 1 | 2013 | 1247 | 0.070 |
Why?
|
| Unnecessary Procedures | 1 | 2010 | 412 | 0.070 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2008 | 345 | 0.070 |
Why?
|
| Cicatrix | 1 | 2013 | 796 | 0.070 |
Why?
|
| Adolescent | 6 | 2022 | 88811 | 0.070 |
Why?
|
| Phosphorylcholine | 1 | 2007 | 151 | 0.070 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 2331 | 0.070 |
Why?
|
| Renin-Angiotensin System | 1 | 2011 | 736 | 0.070 |
Why?
|
| Rest | 1 | 2011 | 940 | 0.070 |
Why?
|
| Renal Dialysis | 1 | 2016 | 1791 | 0.070 |
Why?
|
| Hypolipidemic Agents | 1 | 1991 | 609 | 0.070 |
Why?
|
| Body Height | 1 | 2012 | 1561 | 0.060 |
Why?
|
| Risk | 3 | 2011 | 9599 | 0.060 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2011 | 4055 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 1991 | 770 | 0.060 |
Why?
|
| Lactic Acid | 1 | 2011 | 1137 | 0.060 |
Why?
|
| Phenols | 1 | 1990 | 526 | 0.060 |
Why?
|
| Angioplasty, Balloon | 1 | 2009 | 591 | 0.060 |
Why?
|
| Brain Edema | 1 | 2010 | 601 | 0.060 |
Why?
|
| Drug Discovery | 1 | 2013 | 1062 | 0.060 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2010 | 1143 | 0.060 |
Why?
|
| Kidney Diseases | 2 | 2013 | 2100 | 0.060 |
Why?
|
| Saphenous Vein | 1 | 2008 | 519 | 0.060 |
Why?
|
| Proportional Hazards Models | 6 | 2016 | 12529 | 0.060 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2008 | 539 | 0.060 |
Why?
|
| Advisory Committees | 1 | 2009 | 796 | 0.060 |
Why?
|
| Molecular Structure | 1 | 2009 | 1880 | 0.060 |
Why?
|
| Embolism | 1 | 2008 | 401 | 0.060 |
Why?
|
| Aortic Valve | 3 | 2022 | 1964 | 0.060 |
Why?
|
| Coronary Restenosis | 2 | 2007 | 396 | 0.060 |
Why?
|
| Databases as Topic | 1 | 2006 | 472 | 0.060 |
Why?
|
| Intracranial Hemorrhages | 1 | 2010 | 809 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 1060 | 0.060 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2011 | 1513 | 0.060 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2006 | 391 | 0.060 |
Why?
|
| Reflex | 1 | 2006 | 376 | 0.060 |
Why?
|
| Arrhythmia, Sinus | 1 | 2004 | 48 | 0.060 |
Why?
|
| Aging | 3 | 1992 | 8725 | 0.060 |
Why?
|
| Lipids | 2 | 1992 | 3317 | 0.060 |
Why?
|
| Sex Distribution | 1 | 2009 | 2269 | 0.060 |
Why?
|
| Reproducibility of Results | 4 | 2018 | 20133 | 0.060 |
Why?
|
| Triglycerides | 2 | 1992 | 2440 | 0.060 |
Why?
|
| Hypercholesterolemia | 1 | 1991 | 1148 | 0.050 |
Why?
|
| Probability | 1 | 2009 | 2474 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 5 | 2022 | 5531 | 0.050 |
Why?
|
| Combined Modality Therapy | 2 | 2006 | 8522 | 0.050 |
Why?
|
| Patient Admission | 1 | 2011 | 1365 | 0.050 |
Why?
|
| Confidence Intervals | 1 | 2009 | 2915 | 0.050 |
Why?
|
| Vagus Nerve | 1 | 2006 | 458 | 0.050 |
Why?
|
| Hypertrophy, Left Ventricular | 2 | 2009 | 855 | 0.050 |
Why?
|
| Age Distribution | 1 | 2009 | 2864 | 0.050 |
Why?
|
| Kidney Failure, Chronic | 1 | 2016 | 2504 | 0.050 |
Why?
|
| Endosonography | 1 | 2007 | 626 | 0.050 |
Why?
|
| Atherectomy, Coronary | 1 | 2003 | 137 | 0.050 |
Why?
|
| Hypotension, Orthostatic | 1 | 2006 | 258 | 0.050 |
Why?
|
| Atrial Function, Right | 1 | 2002 | 32 | 0.050 |
Why?
|
| Massachusetts | 1 | 2016 | 8882 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2017 | 6503 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2009 | 857 | 0.050 |
Why?
|
| Subarachnoid Hemorrhage | 1 | 2010 | 1022 | 0.050 |
Why?
|
| Office Visits | 1 | 2006 | 594 | 0.050 |
Why?
|
| Diagnosis, Differential | 4 | 2020 | 12973 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 2823 | 0.050 |
Why?
|
| Bundle of His | 1 | 2021 | 102 | 0.050 |
Why?
|
| Reoperation | 1 | 2012 | 4308 | 0.050 |
Why?
|
| Recovery of Function | 1 | 2011 | 2963 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 1429 | 0.050 |
Why?
|
| Atrioventricular Node | 1 | 2021 | 180 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2004 | 1587 | 0.040 |
Why?
|
| Ventricular Remodeling | 2 | 2009 | 1276 | 0.040 |
Why?
|
| Case-Control Studies | 4 | 2020 | 22228 | 0.040 |
Why?
|
| Education, Medical | 1 | 2012 | 1744 | 0.040 |
Why?
|
| Sirolimus | 1 | 2007 | 1541 | 0.040 |
Why?
|
| Ethanol | 1 | 2006 | 1325 | 0.040 |
Why?
|
| Coronary Circulation | 4 | 2008 | 1601 | 0.040 |
Why?
|
| Mitral Valve | 1 | 2008 | 1475 | 0.040 |
Why?
|
| Rifampin | 1 | 2021 | 350 | 0.040 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2008 | 2769 | 0.040 |
Why?
|
| Electric Stimulation | 1 | 2004 | 1738 | 0.040 |
Why?
|
| Disease Management | 2 | 2015 | 2530 | 0.040 |
Why?
|
| Survival Rate | 4 | 2016 | 12822 | 0.040 |
Why?
|
| International Classification of Diseases | 1 | 2025 | 934 | 0.040 |
Why?
|
| Antidepressive Agents | 1 | 2011 | 2901 | 0.040 |
Why?
|
| Sensitivity and Specificity | 5 | 2008 | 14643 | 0.040 |
Why?
|
| Belgium | 1 | 2018 | 119 | 0.040 |
Why?
|
| Double-Blind Method | 5 | 2016 | 12417 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 3928 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2005 | 1318 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2020 | 583 | 0.040 |
Why?
|
| Disease Progression | 2 | 2012 | 13614 | 0.040 |
Why?
|
| Blood Coagulation | 1 | 2003 | 1171 | 0.040 |
Why?
|
| Acute Coronary Syndrome | 1 | 2010 | 2185 | 0.030 |
Why?
|
| Catecholamines | 1 | 1998 | 385 | 0.030 |
Why?
|
| Coronary Stenosis | 1 | 2003 | 798 | 0.030 |
Why?
|
| Image Enhancement | 1 | 2007 | 2857 | 0.030 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 6306 | 0.030 |
Why?
|
| Cholesterol, HDL | 3 | 1992 | 1813 | 0.030 |
Why?
|
| Coronary Vessels | 1 | 2007 | 3094 | 0.030 |
Why?
|
| Clinical Protocols | 2 | 2016 | 1435 | 0.030 |
Why?
|
| Prostheses and Implants | 2 | 2016 | 1273 | 0.030 |
Why?
|
| Costs and Cost Analysis | 2 | 2000 | 1666 | 0.030 |
Why?
|
| Prevalence | 5 | 2016 | 15828 | 0.030 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2006 | 1456 | 0.030 |
Why?
|
| Patient Participation | 1 | 2005 | 1447 | 0.030 |
Why?
|
| Troponin T | 1 | 2020 | 785 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 6838 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2022 | 1740 | 0.030 |
Why?
|
| Life Style | 1 | 2006 | 3928 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2007 | 3360 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
| Panic Disorder | 1 | 1998 | 611 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 4213 | 0.030 |
Why?
|
| Family Practice | 1 | 1997 | 508 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2008 | 3247 | 0.030 |
Why?
|
| Cause of Death | 1 | 2004 | 3715 | 0.030 |
Why?
|
| Antimalarials | 1 | 2020 | 910 | 0.030 |
Why?
|
| Immunoglobulin Fab Fragments | 2 | 2006 | 443 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2021 | 2353 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2020 | 20690 | 0.030 |
Why?
|
| Antitubercular Agents | 1 | 2021 | 1380 | 0.030 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2019 | 704 | 0.030 |
Why?
|
| Medicare Payment Advisory Commission | 1 | 2012 | 14 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 2022 | 7473 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 1999 | 1470 | 0.030 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 2 | 2006 | 577 | 0.020 |
Why?
|
| Databases, Factual | 2 | 2019 | 8060 | 0.020 |
Why?
|
| American Heart Association | 2 | 2006 | 1045 | 0.020 |
Why?
|
| Catheterization | 1 | 2017 | 1426 | 0.020 |
Why?
|
| Hyperlipoproteinemias | 1 | 1991 | 19 | 0.020 |
Why?
|
| Clofibric Acid | 1 | 1991 | 8 | 0.020 |
Why?
|
| Regression Analysis | 2 | 2014 | 6321 | 0.020 |
Why?
|
| Bezafibrate | 1 | 1991 | 14 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2008 | 1238 | 0.020 |
Why?
|
| Fibric Acids | 1 | 1991 | 27 | 0.020 |
Why?
|
| Research Design | 1 | 2006 | 6204 | 0.020 |
Why?
|
| Niacin | 1 | 1991 | 116 | 0.020 |
Why?
|
| Hypertension | 1 | 2010 | 8616 | 0.020 |
Why?
|
| Fenofibrate | 1 | 1991 | 87 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 1991 | 361 | 0.020 |
Why?
|
| Pandemics | 2 | 2020 | 8721 | 0.020 |
Why?
|
| Surgical Staplers | 1 | 2010 | 34 | 0.020 |
Why?
|
| Durable Medical Equipment | 1 | 2009 | 23 | 0.020 |
Why?
|
| Ganglia, Autonomic | 1 | 2010 | 44 | 0.020 |
Why?
|
| Syncope, Vasovagal | 1 | 2009 | 39 | 0.020 |
Why?
|
| Contrast Media | 2 | 2016 | 5330 | 0.020 |
Why?
|
| New York City | 1 | 1992 | 736 | 0.020 |
Why?
|
| Lovastatin | 1 | 1989 | 114 | 0.020 |
Why?
|
| Terminology as Topic | 2 | 2006 | 1536 | 0.020 |
Why?
|
| Models, Educational | 1 | 2012 | 375 | 0.020 |
Why?
|
| Calibration | 1 | 2011 | 812 | 0.020 |
Why?
|
| Dehydration | 1 | 2009 | 215 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2016 | 996 | 0.020 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2008 | 109 | 0.020 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2010 | 262 | 0.020 |
Why?
|
| Coronary Occlusion | 1 | 2011 | 284 | 0.020 |
Why?
|
| Epidemiologic Methods | 1 | 2012 | 1325 | 0.020 |
Why?
|
| Systole | 1 | 2010 | 935 | 0.020 |
Why?
|
| Coronary Artery Disease | 1 | 2007 | 6544 | 0.020 |
Why?
|
| Equipment Safety | 1 | 2008 | 250 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 1637 | 0.020 |
Why?
|
| Anxiety Disorders | 1 | 1998 | 2739 | 0.020 |
Why?
|
| Dementia | 2 | 1992 | 2741 | 0.020 |
Why?
|
| Hypoxia-Ischemia, Brain | 1 | 2010 | 361 | 0.020 |
Why?
|
| Polysomnography | 1 | 2013 | 1868 | 0.020 |
Why?
|
| Prosthesis Design | 1 | 2013 | 2111 | 0.020 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 998 | 0.020 |
Why?
|
| Cholesterol, LDL | 2 | 1992 | 2395 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2008 | 1154 | 0.020 |
Why?
|
| Arteriosclerosis | 1 | 1990 | 1055 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2010 | 1835 | 0.020 |
Why?
|
| Markov Chains | 1 | 2009 | 971 | 0.020 |
Why?
|
| Propensity Score | 1 | 2013 | 1971 | 0.020 |
Why?
|
| Tunica Intima | 1 | 2007 | 455 | 0.010 |
Why?
|
| Gadolinium DTPA | 1 | 2008 | 822 | 0.010 |
Why?
|
| Constriction, Pathologic | 1 | 2008 | 1102 | 0.010 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2010 | 611 | 0.010 |
Why?
|
| Echocardiography, Doppler | 1 | 2008 | 899 | 0.010 |
Why?
|
| Drug Therapy | 1 | 2007 | 504 | 0.010 |
Why?
|
| Tachycardia, Sinus | 1 | 2003 | 43 | 0.010 |
Why?
|
| Observer Variation | 1 | 2010 | 2611 | 0.010 |
Why?
|
| Ticlopidine | 1 | 2008 | 730 | 0.010 |
Why?
|
| Triage | 1 | 2010 | 994 | 0.010 |
Why?
|
| Animals | 3 | 2011 | 168735 | 0.010 |
Why?
|
| Calcium Channel Blockers | 1 | 2005 | 685 | 0.010 |
Why?
|
| Lung | 1 | 2020 | 10046 | 0.010 |
Why?
|
| Ultrasonography, Interventional | 1 | 2010 | 1519 | 0.010 |
Why?
|
| Survivors | 1 | 2011 | 2373 | 0.010 |
Why?
|
| Heart Septum | 1 | 2001 | 303 | 0.010 |
Why?
|
| Brain | 1 | 2007 | 27179 | 0.010 |
Why?
|
| Microcirculation | 1 | 2005 | 1282 | 0.010 |
Why?
|
| Health Care Surveys | 1 | 2007 | 2426 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 14745 | 0.010 |
Why?
|
| Quinidine | 1 | 1998 | 52 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 2 | 2006 | 9239 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2350 | 0.010 |
Why?
|
| Emergency Medicine | 1 | 2007 | 1222 | 0.010 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 2132 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 4851 | 0.010 |
Why?
|
| Treatment Failure | 1 | 2003 | 2653 | 0.010 |
Why?
|
| Aspirin | 1 | 2008 | 3135 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2009 | 6251 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 4037 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 1989 | 3249 | 0.010 |
Why?
|
| Hospital Mortality | 1 | 2008 | 5339 | 0.010 |
Why?
|
| Models, Biological | 1 | 2009 | 9443 | 0.010 |
Why?
|
| Radiography | 1 | 2003 | 6941 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2013 | 26282 | 0.010 |
Why?
|
| Child | 1 | 1997 | 80568 | 0.000 |
Why?
|
| Lipoproteins, HDL | 1 | 1991 | 676 | 0.000 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1991 | 12235 | 0.000 |
Why?
|
| Hyperlipoproteinemia Type II | 1 | 1991 | 396 | 0.000 |
Why?
|
| Anticholesteremic Agents | 1 | 1991 | 970 | 0.000 |
Why?
|
| Cholesterol | 1 | 1992 | 2902 | 0.000 |
Why?
|